10-Q 1 silk-20240331x10q.htm 10-Q silk-20240331x10q
false--12-31Q120240001397702YesYesP3Y0001397702us-gaap:EmployeeStockOptionMembersilk:TwoThousandNineteenStockOptionPlanMember2024-01-012024-03-310001397702us-gaap:CommonStockMember2024-01-012024-03-310001397702us-gaap:CommonStockMember2023-01-012023-03-310001397702us-gaap:RetainedEarningsMember2024-03-310001397702us-gaap:AdditionalPaidInCapitalMember2024-03-310001397702us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001397702us-gaap:RetainedEarningsMember2023-12-310001397702us-gaap:AdditionalPaidInCapitalMember2023-12-310001397702us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001397702us-gaap:RetainedEarningsMember2023-03-310001397702us-gaap:AdditionalPaidInCapitalMember2023-03-310001397702us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001397702us-gaap:RetainedEarningsMember2022-12-310001397702us-gaap:AdditionalPaidInCapitalMember2022-12-310001397702us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001397702us-gaap:CommonStockMember2024-03-310001397702us-gaap:CommonStockMember2023-12-310001397702us-gaap:CommonStockMember2023-03-310001397702us-gaap:CommonStockMember2022-12-3100013977022023-01-012023-12-310001397702silk:BenchmarkMemberus-gaap:PerformanceSharesMember2024-03-012024-03-310001397702us-gaap:RestrictedStockUnitsRSUMember2023-12-310001397702us-gaap:PerformanceSharesMember2023-12-310001397702us-gaap:PerformanceSharesMember2024-03-012024-03-310001397702us-gaap:RestrictedStockUnitsRSUMembersilk:TwoThousandNineteenStockOptionPlanMember2024-01-012024-03-310001397702us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001397702us-gaap:PerformanceSharesMember2024-01-012024-03-3100013977022023-05-012023-05-310001397702us-gaap:RetainedEarningsMember2024-01-012024-03-310001397702us-gaap:RetainedEarningsMember2023-01-012023-03-310001397702us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001397702us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001397702us-gaap:RevolvingCreditFacilityMembersilk:OxfordFinanceMembersilk:TermLoanMember2024-03-310001397702us-gaap:RevolvingCreditFacilityMembersilk:OxfordFinanceMemberus-gaap:SecuredDebtMember2022-05-310001397702us-gaap:RevolvingCreditFacilityMembersilk:OxfordFinanceMembersilk:TermLoanMember2022-05-310001397702silk:StifelBankMemberus-gaap:SecuredDebtMember2022-05-310001397702silk:LoanAndSecurityAgreementMembersilk:OxfordFinanceMember2022-05-310001397702us-gaap:LetterOfCreditMembersilk:OxfordFinanceMember2024-01-012024-03-310001397702us-gaap:LetterOfCreditMembersilk:OxfordFinanceMember2024-03-310001397702silk:HeadquartersMember2024-03-310001397702silk:AdditionalOfficeLaboratoryAndManufacturingSpaceMember2024-03-3100013977022023-05-310001397702silk:StifelBankMembersilk:TermLoanMember2022-05-012022-05-310001397702us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001397702us-gaap:EmployeeStockMember2024-01-012024-03-310001397702silk:LoanFacilityMembersilk:StifelBankMember2022-05-270001397702silk:TermLoanTrancheCMembersilk:TermLoanMember2022-05-310001397702silk:TermLoanTrancheBMembersilk:TermLoanMember2022-05-310001397702silk:TermLoanTrancheAMembersilk:TermLoanMember2022-05-310001397702us-gaap:RevolvingCreditFacilityMembersilk:OxfordFinanceMembersilk:IndexRateMember2022-05-012022-05-3100013977022023-03-3100013977022022-12-310001397702us-gaap:MoneyMarketFundsMember2024-03-310001397702us-gaap:MoneyMarketFundsMember2023-12-310001397702us-gaap:USTreasurySecuritiesMember2024-03-310001397702us-gaap:CommercialPaperMember2024-03-310001397702us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001397702us-gaap:CorporateDebtSecuritiesMember2024-03-310001397702silk:AgencyNotesMember2024-03-310001397702us-gaap:USTreasurySecuritiesMember2023-12-310001397702us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001397702us-gaap:CorporateDebtSecuritiesMember2023-12-310001397702us-gaap:CommercialPaperMember2023-12-310001397702silk:AgencyNotesMember2023-12-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-03-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembersilk:AgencyNotesMember2024-03-310001397702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001397702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-03-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-03-310001397702us-gaap:FairValueMeasurementsRecurringMembersilk:AgencyNotesMember2024-03-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001397702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001397702us-gaap:FairValueMeasurementsRecurringMember2024-03-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-12-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembersilk:AgencyNotesMember2023-12-310001397702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001397702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001397702us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-12-310001397702us-gaap:FairValueMeasurementsRecurringMembersilk:AgencyNotesMember2023-12-310001397702us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001397702us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001397702us-gaap:FairValueMeasurementsRecurringMember2023-12-310001397702us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001397702silk:RestrictedStockUnitsAndPerformanceStockUnitsMember2024-01-012024-03-310001397702us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001397702silk:RestrictedStockUnitsAndPerformanceStockUnitsMember2023-01-012023-03-310001397702us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310001397702us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001397702us-gaap:CostOfSalesMember2024-01-012024-03-310001397702us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-310001397702us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001397702us-gaap:CostOfSalesMember2023-01-012023-03-310001397702us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001397702us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001397702us-gaap:RestrictedStockUnitsRSUMember2024-03-310001397702us-gaap:PerformanceSharesMember2024-03-310001397702silk:TwoThousandNineteenStockOptionPlanMember2024-03-310001397702silk:TwoThousandNineteenStockOptionPlanMember2023-12-310001397702silk:TwoThousandNineteenStockOptionPlanMember2024-01-012024-03-310001397702srt:MaximumMemberus-gaap:PerformanceSharesMembersilk:TwoThousandNineteenStockOptionPlanMember2024-03-012024-03-310001397702silk:TermLoanMember2024-03-310001397702silk:LoanAndSecurityAgreementMembersilk:OxfordFinanceMembersilk:TermLoanMember2022-05-310001397702srt:MaximumMembersilk:SecuredTermLoanFacilityMembersilk:OxfordFinanceMember2024-01-012024-03-310001397702silk:LoanAndSecurityAgreementMembersilk:OxfordFinanceMembersilk:TermLoanMember2022-05-012022-05-310001397702silk:OxfordFinanceMembersilk:TermLoanMember2024-01-012024-03-3100013977022023-01-012023-03-310001397702us-gaap:RevolvingCreditFacilityMembersilk:OxfordFinanceMembersilk:IndexRateMember2024-01-012024-03-310001397702us-gaap:RevolvingCreditFacilityMembersilk:OxfordFinanceMember2022-05-012022-05-310001397702silk:OxfordFinanceMember2024-01-012024-03-310001397702us-gaap:EmployeeStockOptionMembersilk:TwoThousandNineteenStockOptionPlanMember2024-03-310001397702us-gaap:RevolvingCreditFacilityMembersilk:OxfordFinanceMember2024-01-012024-03-3100013977022023-12-3100013977022024-03-3100013977022024-04-3000013977022024-01-012024-03-31silk:segmentiso4217:USDxbrli:sharesxbrli:pureiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________

FORM 10-Q

______________________________

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from               to

Commission File Number:   001-38847     

______________________________

SILK ROAD MEDICAL, INC.

(Exact name of registrant as specified in its charter)

______________________________

Delaware

20-8777622

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1213 Innsbruck Dr., Sunnyvale, CA 94089

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (408) 720-9002

_______________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

SILK

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes     No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes     No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐    No 

As of April 30, 2024, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 39,443,868.

TABLE OF CONTENTS

 

As used in this report, references to “Silk Road Medical,” the “Company,” “we,” “our” or “us,” unless the context otherwise requires, refer to Silk Road Medical, Inc.

“Silk Road Medical,” the “Silk Road Medical” logo, “TCAR,” “ENROUTE,” the “ENROUTE” logo, “ENHANCE,” “Enflate” and our other registered or common law trade names, trademarks or service marks appearing in this Quarterly Report on Form 10-Q are our property. Trade names, trademarks and service marks of other companies appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies unless otherwise stated. Solely for convenience, the trademarks and trade names referred to in this Quarterly Report on Form 10-Q appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and trade names.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations, and financial performance and condition, as well as our plans, objectives and expectations for our business, operations, prospects, and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of the federal securities laws and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, or the use of future dates.

These forward-looking statements include, but are not limited to, statements about the following subjects:

our goal to establish transcarotid artery revascularization, or TCAR, as the standard of care for the treatment of carotid artery disease;

our 2024 strategic priorities to grow, strengthen and diversify our business;

our plans to conduct further clinical trials and anticipated enrollment, clinical sites, completion, results and timing thereof;

our plans and expected timeline related to our products, including timing of commercial launch, or developing new products, to address additional indications or to obtain regulatory approvals or clearances or otherwise;

the expected use of our products by physicians, including market awareness, acceptance and adoption of our products, and anticipated increased utilization of our products and market penetration;

our expectations regarding the number of procedures that will be performed with our products, the number of physicians we expect to train, and the number of our sales territories;

our ability to obtain, maintain and expand regulatory approvals and clearances for our current products and any new products we create;

the expected growth of our business and our organization;

our expectations regarding government and third-party payer coverage and reimbursement and the anticipated effect of such decisions;

our ability to manage our Chief Executive Officer transition and retain and recruit key personnel, including the continued expansion of our sales and marketing infrastructure, and the anticipated timing and effect of such actions;

our ability to obtain an adequate supply of materials, components and finished goods for our products from our third-party suppliers, most of whom are single-source suppliers;

our ability to manufacture sufficient quantities of our products with sufficient quality and the sufficiency of our current manufacturing capabilities;

our ability to obtain and maintain intellectual property protection for our products and our business;

our ability to expand our business into new geographic markets and the anticipated timing thereof, including in Japan and China;

our compliance with extensive Nasdaq and U.S. Securities and Exchange Commission, or SEC, requirements and government laws, rules and regulations both in the United States and internationally;

our expectations regarding operating trends, future financial performance and expense management and our estimates of our future expenses, ongoing losses, future revenue, including per procedure revenue and the effect thereon of new products, gross margins, operating leverage, capital requirements and our need for, or ability to obtain, additional financing;

our ability to identify and develop new and planned products and/or acquire new products; 

our experience with inflationary and price pressures and increased labor costs and labor and staffing shortages;

developments and projections relating to our market opportunity and penetration, competitors or our industry; and

our intended use of net proceeds from our public offerings.

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q.

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or changes in our expectations. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the SEC as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

 

Part I. Financial Information

Item 1: Condensed Financial Statements

 

Silk Road Medical, Inc.

Condensed Balance Sheets

(unaudited)

(in thousands, except share and per share data)

March 31,

December 31,

2024

2023

Assets

Current assets:

Cash and cash equivalents

$

22,629 

$

20,210 

Short-term investments

151,833 

161,264 

Accounts receivable, net

27,203 

23,573 

Inventories

30,486 

29,876 

Prepaid expenses and other current assets

3,543 

5,912 

Total current assets

235,694 

240,835 

Long-term investments

2,027 

9,456 

Property and equipment, net

8,085 

8,114 

Other non-current assets

6,508 

6,904 

Total assets

$

252,314 

$

265,309 

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$

2,966 

$

5,676 

Accrued liabilities

18,371 

24,607 

Total current liabilities

21,337 

30,283 

Long-term debt

75,886 

75,626 

Other liabilities

7,806 

8,249 

Total liabilities

105,029 

114,158 

Commitments and contingencies (Note 7)

 

 

Stockholders' equity:

Preferred stock, $0.001 par value

Shares authorized: 5,000,000 at March 31, 2024 and December 31, 2023

Shares issued and outstanding: none at March 31, 2024 and December 31, 2023

Common stock, $0.001 par value

Shares authorized: 100,000,000 at March 31, 2024 and December 31, 2023

Shares issued and outstanding: 39,436,634 and 39,165,481 at March 31, 2024 and December 31, 2023, respectively

39 

39 

Additional paid-in capital

560,854 

550,495 

Accumulated other comprehensive income (loss)

(17)

72 

Accumulated deficit

(413,591)

(399,455)

Total stockholders' equity

147,285 

151,151 

Total liabilities and stockholders' equity

$

252,314 

$

265,309 

 

The accompanying notes are an integral part of these condensed financial statements.

4


Silk Road Medical, Inc.

Condensed Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share data)

Three Months Ended

March 31,

2024

2023

Revenue

$

48,484 

$

40,131 

Cost of goods sold

11,983 

12,526 

Gross profit

36,501 

27,605 

Operating expenses:

Research and development

10,660 

10,433 

Selling, general and administrative

40,775 

34,082 

Total operating expenses

51,435 

44,515 

Loss from operations

(14,934)

(16,910)

Interest income

2,471 

2,287 

Interest expense

(1,721)

(1,693)

Other income (expense), net

48 

(144)

Net loss

(14,136)

(16,460)

Other comprehensive income (loss):

Unrealized gain (loss) on investments, net

(89)

249 

Other comprehensive income (loss)

(89)

249 

Comprehensive loss

$

(14,225)

$

(16,211)

Net loss per share, basic and diluted

$

(0.36)

$

(0.43)

Weighted average common shares used to compute net loss per share, basic and diluted

39,261,496 

38,532,202 

The accompanying notes are an integral part of these condensed financial statements.

5


Silk Road Medical, Inc.

Condensed Statements of Stockholders' Equity

(unaudited)

(in thousands, except share data)

Common Stock

Additional
Paid-in

Accumulated

Accumulated
Other Comprehensive

Shares

Amount

Capital

Deficit

Income (Loss)

Total

Balances at December 31, 2023

39,165,481 

$

39 

$

550,495 

$

(399,455)

$

72 

$

151,151 

Issuance of common stock upon vesting of restricted stock units

271,153 

— 

— 

— 

— 

Stock-based compensation

— 

— 

10,359 

— 

— 

10,359 

Net loss

— 

— 

— 

(14,136)

— 

(14,136)

Unrealized loss on investments, net

— 

— 

— 

(89)

(89)

Balances at March 31, 2024

39,436,634 

$

39 

$

560,854 

$

(413,591)

$

(17)

$

147,285 

(in thousands, except share data)

Common Stock

Additional
Paid-in

Accumulated

Accumulated
Other Comprehensive

Shares

Amount

Capital

Deficit

Income (Loss)

Total

Balances at December 31, 2022

38,355,972 

$

38 

$

507,715 

$

(343,712)

$

(166)

$

163,875 

Exercise of stock options

144,474 

— 

1,110 

— 

— 

1,110 

Issuance of common stock upon vesting of restricted stock units

207,995 

1

— 

— 

1 

Stock-based compensation

— 

— 

8,838 

— 

— 

8,838 

Net loss

— 

— 

— 

(16,460)

— 

(16,460)

Unrealized gain on investments, net

— 

— 

— 

— 

249

249 

Balances at March 31, 2023

38,708,441 

$

39 

$

517,663 

$

(360,172)

$

83 

$

157,613 

The accompanying notes are an integral part of these condensed financial statements.

6


Silk Road Medical, Inc.

Condensed Statements of Cash Flows

(unaudited)

(in thousands)

Three Months Ended

March 31,

2024

2023

Cash flows from operating activities

Net loss

$

(14,136)

$

(16,460)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization expense

644 

699 

Stock-based compensation expense

10,359 

8,838 

Accretion of discounts on investments, net

(1,359)

(1,753)

Amortization of debt discount and debt issuance costs

59 

57 

Amortization of right-of-use asset

281 

281 

Non-cash interest expense

222 

218 

Loss on disposal of property and equipment

144 

Provision for doubtful accounts receivable

19 

Provision for excess and obsolete inventories

175 

1 

Changes in assets and liabilities:

Accounts receivable

(3,630)

(1,968)

Inventories

(785)

2,109 

Prepaid expenses and other current assets

2,369 

(124)

Other assets

115 

(17)

Accounts payable

(2,937)

2,668 

Accrued liabilities

(6,256)

(6,388)

Other liabilities

(443)

(471)

Net cash used in operating activities

(15,322)

(12,147)

Cash flows from investing activities

Purchases of property and equipment

(388)

(287)

Purchases of investments

(43,871)

(26,407)

Proceeds from maturity of investments

62,000 

32,800 

Net cash provided by investing activities

17,741 

6,106 

Cash flows from financing activities

Proceeds from issuance of common stock

1,110 

Net cash provided by financing activities

1,110 

Net change in cash, cash equivalents and restricted cash

2,419 

(4,931)

Cash, cash equivalents and restricted cash, beginning of period

20,210 

55,513 

Cash, cash equivalents and restricted cash, end of period

$

22,629 

$

50,582 

Supplemental disclosure of cash flow information

Cash paid for interest

$

1,440 

$

1,418 

Noncash investing and financing activities:

Accounts payable and accrued liabilities for purchases of property and equipment

$

227 

$

58 

 

The accompanying notes are an integral part of these condensed financial statements.

7


Table of Contents

 

Silk Road Medical, Inc.

Notes to Condensed Financial Statements

(unaudited)

1.    Organization

The Company

Silk Road Medical, Inc., or the Company, has developed a technologically advanced, minimally-invasive solution for patients with carotid artery disease who are at risk for stroke. The Company's portfolio of products enable a procedure referred to as transcarotid artery revascularization, or TCAR, that combines the benefits of endovascular techniques and surgical principles. The Company manufactures and sells in the United States its portfolio of TCAR products which are designed to provide direct access to the carotid artery, effective reduction in stroke risk throughout the procedure, and long-term restraint of carotid plaque.

2.    Summary of Significant Accounting Policies

Basis of Preparation

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the condensed balance sheet as of December 31, 2023, and related disclosures, have been derived from the audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company’s condensed financial information. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future year.

The accompanying interim unaudited condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2023 included in the Company's annual report on Form 10-K filed with the SEC on February 28, 2024.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Fair Value of Financial Instruments

The Company has evaluated the estimated fair value of its financial instruments as of March 31, 2024 and December 31, 2023. The carrying amounts of certain of the Company’s financial instruments, which include accounts receivable, accounts payable and accrued liabilities approximate their respective fair values because of the short-term nature of these instruments. Management believes that its debt bears interest at the prevailing market rates for instruments with similar characteristics (Level 2 within the fair value hierarchy); accordingly, the carrying value of this instrument approximates its fair value.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents are recorded at fair value, based on quoted market prices. As of

 

8


Table of Contents

 

Silk Road Medical, Inc.

Notes to Condensed Financial Statements

(unaudited)

March 31, 2024 and December 31, 2023, the Company’s cash equivalents were entirely comprised of investments in money market funds.

Investments

Short-term and long-term investments consist of debt securities classified as available-for-sale. Short-term investment have original maturities greater than 90 days, but less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are recorded at fair value based on the fair value hierarchy. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss). Realized gains and losses are included in earnings and are derived based on the specific-identification method for determining the costs of investments sold and were insignificant for the three months ended March 31, 2024 and 2023. Amortization of premiums and accretion of discounts are reported as a component of interest income.

A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the investment. The Company evaluates the securities in an unrealized loss position for expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, current economic conditions and credit ratings. The Company did not recognize any credit losses on its available-for-sale securities during the three months ended March 31, 2024 and 2023.

Concentration of Credit Risk, and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, U.S. government securities, U.S. treasury bills, agency bonds/notes and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three months ended March 31, 2024 and 2023.

As of March 31, 2024 and December 31, 2023, a portion of the Company’s cash and cash equivalents was maintained with Silicon Valley Bank, a division of First Citizens Bank, or SVB, and exceeded federally insured limits. Substantially all of the Company’s cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. As of the issuance date of these financial statements, the Company has not experienced any losses on its deposits.

The Company’s accounts receivable are due from a variety of hospitals and medical centers in the United States. As of March 31, 2024 and December 31, 2023, no customer represented 10% or more of the Company’s accounts receivable. For the three months ended March 31, 2024 and 2023, there were no customers that represented 10% or more of revenue.

The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.

The Company manufactures certain of its commercial products in-house. Certain of the Company’s finished goods, components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in finished goods, component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.

The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future

 

9


Table of Contents

 

Silk Road Medical, Inc.

Notes to Condensed Financial Statements

(unaudited)

devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, competition, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.

Existing or future devices developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.

Leases

The Company accounts for its leasing arrangements in accordance with Accounting Standards Codification, or ASC 842, “Leases.” The Company considers if an arrangement is a lease at inception if it obtains the right to control the use of an identified asset under a leasing arrangement with an initial term greater than twelve months. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both the right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the identified asset. The Company also evaluates the nature of each lease to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. The Company considers renewal options in the determination of the lease term if the option to renew is reasonably certain. Variable lease costs represent payments that are dependent on usage, a rate or index. Variable lease costs, which consists primarily of taxes, insurance and common area maintenance costs, are expensed as incurred. The Company elected to account for contracts that contain lease and non-lease components as a single component, consistent with its historical practice. The Company does not have any finance leases.

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606, "Revenue from Contracts with Customers." Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.

The Company’s revenue is generated from the sale of its products to hospitals and medical centers in the United States through direct sales representatives and is primarily comprised of product revenue net of returns, administration fees and sales rebates. Revenue is recognized when obligations under the terms of a contract with customers are satisfied, which occurs with the transfer of control of the Company’s products to its customers, either upon shipment of the product or delivery of the product to the customer. The Company’s products are readily available for usage as soon as the customer possesses it. Upon receipt, the customer controls the economic benefits of the product, has significant risks and rewards, and the legal title. The Company has present right to payment; therefore, the transfer of control is deemed to happen at a point in time. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring the goods. The Company is entitled to the total consideration for the products ordered by customers as product pricing is fixed according to the terms of customer contracts and payment terms are short. Administration fees and sales rebates are accounted for as a reduction in revenue, calculated based on the terms agreed to with the customer.

As of March 31, 2024 and December 31, 2023, the Company recorded $379,000 and $227,000, respectively, of unbilled receivables, which are included in accounts receivable, net on the condensed balance sheet, as the Company has an unconditional right to payment as of the end of the applicable period. 

 

10


Table of Contents

 

Silk Road Medical, Inc.

Notes to Condensed Financial Statements

(unaudited)

The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. Costs associated with product sales, which include commissions and royalties, are expensed when incurred because the expense is incurred at a point in time and the amortization period is less than one year. Commissions are recorded as selling expense and royalties are recorded as cost of goods sold in the condensed statements of operations and comprehensive loss.

The Company accepts product returns at its discretion or if the product is defective as manufactured. The Company establishes estimated provisions for returns based on historical experience and considers other factors that it believes could significantly impact its expected returns, which provisions are classified within accrued liabilities on the condensed balance sheet. The Company elected to expense shipping and handling costs as incurred and includes them in the cost of goods sold. In those cases where the Company bills shipping and handling costs to customers, it will classify the amounts billed as a component of revenue.

Cost of Goods Sold

The Company manufactures certain of its portfolio of TCAR products at its California and Minnesota facilities and purchases other products from third party manufacturers. Cost of goods sold consists primarily of costs related to materials, components and sub-assemblies, manufacturing overhead costs, direct labor, scrap, product rework, reserves for excess, obsolete and non-sellable inventories as well as logistics-related expenses. A significant portion of the Company’s cost of goods sold currently consists of manufacturing overhead costs. These overhead costs include the cost of quality control, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalties.

Stock–Based Compensation

The Company accounts for stock-based compensation in accordance with Financial Accounting Standards Board, or FASB, ASC 718, "Compensation-Stock Compensation." ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units, performance stock units, and shares issued under its employee stock purchase plan. ASC 718 requires companies to estimate the fair value of all share-based payment option awards on the date of grant using an option pricing model. The fair value of stock options is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period), on a straight-line basis. The Company accounts for option forfeitures as they occur.

The Company accounts for stock-based compensation for restricted stock units at their fair value, based on the closing market price of the Company’s common stock on the date of grant. These costs are recognized on a straight-line basis over the requisite service period, which is usually the vesting period.

The Company accounts for stock-based compensation for performance stock units with market-based conditions at their fair value on the date of the award using the Monte Carlo simulation model. These costs are recognized over the requisite service period, which is usually the vesting period, regardless of the likelihood of achievement of the market-based performance criteria.

The Company accounts for stock-based compensation for its employee stock purchase plan based on the estimated fair value on the first day of the offering period using an option pricing model for each purchase period. These costs are recognized on a straight-line basis over the offering period.

Income Taxes

The Company accounts for income taxes under the liability method, whereby deferred tax assets and liabilities are determined based on the difference between the condensed financial statements and tax bases of assets and liabilities using the enacted tax rates in effect for the year in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

 

11


Table of Contents

 

Silk Road Medical, Inc.

Notes to Condensed Financial Statements

(unaudited)

As the Company has historically incurred operating losses, it has established a full valuation allowance against its net deferred tax assets, and there is no provision for income taxes.

The Company also follows the provisions of ASC 740-10, "Accounting for Uncertainty in Income Taxes." ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. No liability related to uncertain tax positions is recorded on the condensed financial statements. It is the Company's policy to include penalties and interest expense related to income taxes as part of the provision for income taxes.

Comprehensive Loss

Comprehensive loss consists of net loss and changes in unrealized gains and losses on investments classified as available-for-sale. For the three months ended March 31, 2024 and 2023, the Company’s unrealized gains and losses on available-for-sale investments represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the condensed statements of operations and comprehensive loss. Accumulated other comprehensive income (loss) is presented in the accompanying condensed balance sheets as a component of stockholders' equity.

Net Loss per Share

Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, common stock options, restricted stock units and performance stock units are considered to be potentially dilutive securities. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive.

Net loss per share was determined as follows (in thousands, except share and per share data):

Three Months Ended

March 31,

2024

2023

Net loss

$

(14,136)

$

(16,460)

Weighted average common stock outstanding used to compute net loss per share, basic and diluted

39,261,496 

38,532,202 

Net loss per share, basic and diluted

$

(0.36)

$

(0.43)

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company's net loss:

March 31,

2024

2023

Common stock options

3,617,465 

3,689,853 

Restricted stock units and performance stock units

4,512,326 

1,692,645 

Total

8,129,791 

5,382,498 

Segment and Geographical Information

The Company operates and manages its business as one reportable and operating segment. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Primarily all of the Company’s long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment. All of the Company’s revenue was in the United States for the three months ended March 31, 2024 and 2023, based on the shipping location of the external customer.

 

12


Table of Contents

 

Silk Road Medical, Inc.

Notes to Condensed Financial Statements

(unaudited)

3.    Recent Accounting Pronouncements

Recently Issued Accounting Standards

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segments expenses. ASU 2023-07 became effective for the Company on January 1, 2024. The adoption of ASU 2023-07 did not have a material impact on the Company’s segment reporting disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09, which enhances income tax disclosure requirements by requiring specified categories and greater disaggregation within the rate reconciliation table, disclosure of income taxes paid by jurisdiction, and providing clarification on uncertain tax positions and related financial statement impacts. ASU 2023-09 is effective for the Company on January 1, 2025 with early adoption permitted. The Company is currently evaluating the impact of adoption of this new guidance on its income tax disclosures..

 

4.    Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

Level 1 – quoted prices in active markets for identical assets and liabilities;

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities;

Level 3 – unobservable inputs.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company’s investments are classified within Level 1 of the fair value hierarchy include money market funds valued using quoted market prices and U.S. treasury bills valued using broker or dealer quotations with reasonable levels of price transparency. Investments classified within Level 2 include commercial paper, which are valued using model-based valuation techniques, and corporate bonds/notes, U.S. government securities and agency bonds/notes, which are valued based upon quoted market prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.

 

13


Table of Contents

 

Silk Road Medical, Inc.

Notes to Condensed Financial Statements

(unaudited)

The following tables set forth by level within the fair value hierarchy the Company’s assets that are reported at fair value as of March 31, 2024 and December 31, 2023, using the inputs defined above (in thousands):

March 31, 2024

Level 1

Level 2

Level 3

Total

Assets:

Money market funds

$

22,355 

$

— 

$

— 

$

22,355 

U.S. treasury bills

8,911 

— 

— 

8,911 

Commercial paper

— 

12,568 

— 

12,568 

Corporate bonds/notes

— 

28,522 

— 

28,522 

U.S. government securities